Gilead Sciences Inc. (NASDAQ:GILD) does about 9.36M shares in volume on a normal day but saw 6681066 shares change hands in Friday trading. The company now has a market cap of 82.18B USD and an enterprise value of about $87.37B. Its current market price is $65.26, marking a decrease of -0.44% compared to the previous close of $65.55. The 52 week high reached by this stock is $85.97 whilst the lowest price level in 52 weeks is $60.89. The script in recent trading has seen the stock touch a high of $65.745 and a low of $64.98.
Gilead Sciences Inc. (GILD) has a 20-day trading average at $67.85 and the current price is -24.09% off the 52-week high compared with 7.18% distance from its 52-week low. The 50-day simple moving average of the closing price is $72.46 and its 200-day simple moving average is $71.54. If we look at the stock’s price movements over the week, volatility stands at 1.21%, which increases to 1.80% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 29.48 to suggest the stock is oversold.
30 analysts observing the Gilead Sciences Inc. (GILD) stock have set the 12-month price targets for the company’s shares at between $62.00 and $94.00. The consensus objective for the share price is $77.75, suggesting that the stock has a potential upside of 16.06% over the period. The median price target is 17.39% away from the current levels at $79.00.
FactSet Research has provided data showing that 30 brokerages have issued ratings for the stock. 2 analysts have rated it as a sell, while 1 advise that it is a overweight. 10 analysts have rated it as a buy and 17 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 31, 2020 when Wells Fargo reiterated the stock to “Equal Weight” and issued a price target of between $87 and $76. RBC Capital Mkts reiterated its price target at $89-$87.
The current price level is -4.11%, -10.15%, and -8.78% away from its SMA20, SMA50, and SMA200 respectively, with the GILD price moving above the 50-day SMA on August 28. Gilead Sciences Inc. (GILD) stock is down -1.86% over the week and -9.77% over the past month. Its price is 0.43% year-to-date and 2.37% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $1.11 below consensus estimates by -$0.34. The company’s next earnings report is expected on 10/22/2020, with forecasts estimating quarterly EPS at $1.98 and $7.01 for whole year. Expected sales for next quarter are $7.1 billion, which analysts say will come at $24.27 billion for the current fiscal year and next year at $24.05 billion. In addition, estimates put the company’s current quarterly revenue at an average of $6.45 billion.
Its 12-month price target is $79.00. To reach the target analysts have set, the stock logically needs to grow 16.06 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $62.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $94.00.
Outstanding shares total 1.26B with insiders holding 0.41% of the shares and institutional holders owning 80.77% of the company’s common stock. The company has a return on investment of 9.50% and return on equity of -1.20%. The forward price to earnings ratio is 9.31. The beta has a value of 0.57. Price to book ratio is 4.54 and price to sales ratio is 3.71.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Gilead Sciences Inc. (GILD) to 35,655,673 shares, mirroring a recent drop by -0.28%. Vanguard Total Stock Market Index dumped 98690.0 shares of Gilead Sciences Inc. common stock bringing its total worth to about $2.48 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Capital Income Builder, which added 3.85 million shares to end up with 30,288,040 shares worth $2.11 billion. American Mutual Fund raise their holdings by 17.12% in the company over the course of the most recent quarter. It now holds a 2.31% position in Gilead Sciences Inc. thanks to 28.97 million shares amounting to $2.01 billion.